Hospitals and pharmaceutical manufacturers are at odds over revisions to the 340B drug discount program, announced by the Biden administration last week.
The final rule, which will take effect on June 18 after a 60-day comment period, aims to make dispute resolution more accessible and efficient, according to the Health Resources and Services Administration, which oversees the program. Along with lowering barriers to entering the process, the rule requires parties to make a good-faith effort to resolve disputes before bringing them to arbiters and creates an appeals process if either party doesn't like the result.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
